Terms: = Kidney tumors AND CCND2, KIAK0002, 894, ENSG00000118971, P30279, MGC102758 AND Treatment
11 results:
1. Increased level of serum leucine-rich-alpha-2-glycoprotein 1 in patients with clear cell renal cell carcinoma.
Nakanishi S; Goya M; Suda T; Yonamine T; Sugawa A; Saito S
BMC Urol; 2024 Apr; 24(1):94. PubMed ID: 38658967
[TBL] [Abstract] [Full Text] [Related]
2. Gene mutation profiling and clinical significances in patients with renal cell carcinoma.
Wang Y; He P; Zhou X; Wang C; Fu J; Zhang D; Liao D; Zhou Z; Wu C; Gong W
Clinics (Sao Paulo); 2023; 78():100259. PubMed ID: 37515929
[TBL] [Abstract] [Full Text] [Related]
3. Estimating health spending associated with chronic multimorbidity in 2018: An observational study among adults in the United States.
Chang AY; Bryazka D; Dieleman JL
PLoS Med; 2023 Apr; 20(4):e1004205. PubMed ID: 37014826
[TBL] [Abstract] [Full Text] [Related]
4. A New Signature That Predicts Progression-Free Survival of Clear Cell Renal Cell Carcinoma with Anti-PD-1 Therapy.
Lin J; Cai Y; Ma Y; Pan J; Wang Z; Zhang J; Liu Y; Zhao Z
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982415
[TBL] [Abstract] [Full Text] [Related]
5. Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials.
Chihara D; Lin R; Flowers CR; Finnigan SR; Cordes LM; Fukuda Y; Huang EP; Rubinstein LV; Nastoupil LJ; Ivy SP; Doroshow JH; Takebe N
Lancet; 2022 Aug; 400(10351):512-521. PubMed ID: 35964611
[TBL] [Abstract] [Full Text] [Related]
6. Predictive model for recurrence of renal cell carcinoma by comparing pre- and postoperative urinary metabolite concentrations.
Morozumi K; Kawasaki Y; Maekawa M; Takasaki S; Sato T; Shimada S; Kawamorita N; Yamashita S; Mitsuzuka K; Mano N; Ito A
Cancer Sci; 2022 Jan; 113(1):182-194. PubMed ID: 34710258
[TBL] [Abstract] [Full Text] [Related]
7. Serum Hepcidin Levels in Multiple Myeloma.
Victor M; Evgeniy H; Gergana T; Julia P; Vasil V; Borislav M; Ivo B; Zlatina G; Kamen T
Clin Lab; 2017 Jul; 63(7):1273-1277. PubMed ID: 28792693
[TBL] [Abstract] [Full Text] [Related]
8. The Silencing of ccnd2 by Promoter Aberrant Methylation in Renal Cell Cancer and Analysis of the Correlation between ccnd2 Methylation Status and Clinical Features.
Wang L; Cui Y; Zhang L; Sheng J; Yang Y; Kuang G; Fan Y; Zhang Q; Jin J
PLoS One; 2016; 11(9):e0161859. PubMed ID: 27583477
[TBL] [Abstract] [Full Text] [Related]
9. Molecular Mechanism of the Cell Death Induced by the Histone Deacetylase Pan Inhibitor LBH589 (Panobinostat) in Wilms Tumor Cells.
Yan-Fang T; Zhi-Heng L; Li-Xiao X; Fang F; Jun L; Gang L; Lan C; Na-Na W; Xiao-Juan D; Li-Chao S; Wen-Li Z; Pei-Fang X; He Z; Guang-Hao S; Yan-Hong L; Yi-Ping L; Yun-Yun X; Hui-Ting Z; Yi W; Mei-Fang J; Lin L; Jian N; Shao-Yan H; Xue-Ming Z; Xing F; Jian W; Jian P
PLoS One; 2015; 10(7):e0126566. PubMed ID: 26176219
[TBL] [Abstract] [Full Text] [Related]
10. Breast cancer in female survivors of Wilms tumor: a report from the national Wilms tumor late effects study.
Lange JM; Takashima JR; Peterson SM; Kalapurakal JA; Green DM; Breslow NE
Cancer; 2014 Dec; 120(23):3722-30. PubMed ID: 25348097
[TBL] [Abstract] [Full Text] [Related]
11. Impact of clinical and histopathological parameters on disease specific survival in patients with collecting duct renal cell carcinoma: development of a disease specific risk model.
May M; Ficarra V; Shariat SF; Zigeuner R; Chromecki T; Cindolo L; Burger M; Gunia S; Feciche B; Wenzl V; Aziz A; Chun F; Becker A; Pahernik S; Simeone C; Longo N; Zucchi A; Antonelli A; Mirone V; Stief C; Novara G; Brookman-May S; ;
J Urol; 2013 Aug; 190(2):458-63. PubMed ID: 23434943
[TBL] [Abstract] [Full Text] [Related]
